Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma-Reference-Cited by-同舟云学术

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma

Published:2015-06-23 Issue:24 Volume:313 Page:2449
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Loeb Stacy¹,Folkvaljon Yasin²,Lambe Mats³,Robinson David⁴,Garmo Hans⁵,Ingvar Christian⁶,Stattin Pär⁴

Affiliation:

1. Department of Urology, Population Health, and Laura and Isaac Perlmutter Cancer Center, New York University, New York

2. Uppsala University Hospital, Regional Cancer Center, Uppsala, Sweden

3. Uppsala University Hospital, Regional Cancer Center, Uppsala, Sweden3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

4. Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden

5. Division of Cancer Studies, Cancer Epidemiology Group, King's College London, London, United Kingdom

6. Department of Surgery, Melanoma and Breast, Lund University Hospital, Lund, Sweden

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients;Frontiers in Cardiovascular Medicine;2024-03-21

2. PDE5 inhibitors against cancer via mediating immune cells in tumor microenvironment: AI‐based approach for future drug repurposing exploration;Interdisciplinary Medicine;2024-03-16

3. The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review;Journal of Basic and Clinical Physiology and Pharmacology;2023-11-01

4. Naringin corrects renal failure related to Lesch‐Nyhan disease in a rat model via NOS–cAMP–PKA and BDNF/TrkB pathways;Journal of Biochemical and Molecular Toxicology;2023-10-22

5. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis;Sexual Medicine;2023-10-01